Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus. Data Sources: A MEDLINE search (1966–May 2010) was conducted for...
Gespeichert in:
| Veröffentlicht in: | The Annals of pharmacotherapy 2010-10, Vol.44 (10), p.1615-1623 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1623 |
|---|---|
| container_issue | 10 |
| container_start_page | 1615 |
| container_title | The Annals of pharmacotherapy |
| container_volume | 44 |
| creator | Phillippe, Haley M Wargo, Kurt A |
| description | Objective:
To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus.
Data Sources:
A MEDLINE search (1966–May 2010) was conducted for English-language, human studies using the terms mitiglinide, KAD 1229, S 21403, and meglitinide analogs. Abstracts presented at the American Association and European Association for the Study of Diabetes annual meetings from 2005 to 2009 were also evaluated for relevant data.
Study Selection and Data Extraction:
Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide were reviewed.
Data Synthesis:
Mitiglinide has been shown through small clinical studies (N |
| doi_str_mv | 10.1345/aph.1P136 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_755173539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1P136</sage_id><sourcerecordid>755173539</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-5d71ea7ce8d216a19396aa2fdf31769f63799fdd058017968e6760ac63f73653</originalsourceid><addsrcrecordid>eNpt0E1PwjAYwPHGaATRg1_A9KLGw7AvtF29EXxNQD1wX8r2FErGhu1mwre3COrFU5vml6dP_gidU9KnfCBuzXrRp--UywPUpWLAEskUOYx3IklCWEo66CSEJSFEU6aPUYeRdEAFTbvoeeIaNy9d5Qq4w0P8Wn9CiYdzqBpsa4-bBeCpB9Osti-1xdPNGjDD987MoIGAJ1CWrmnDKTqypgxwtj97aPr4MB09J-O3p5fRcJzkcdMmEYWiYFQOacGoNFRzLY1htrCcKqmt5EprWxREpIQqLVOQShKTS24Vl4L30PVu7NrXHy2EJlu5kMcdTAV1GzIlBFVccB3lzU7mvg7Bg83W3q2M32SUZNtsWcyWfWeL9mI_tZ2toPiVP50iuNwDE3JTWm-q3IU_x2NkprfuaueCmUO2rFtfxRj__PgFHAd_Ng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>755173539</pqid></control><display><type>article</type><title>Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Phillippe, Haley M ; Wargo, Kurt A</creator><creatorcontrib>Phillippe, Haley M ; Wargo, Kurt A</creatorcontrib><description>Objective:
To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus.
Data Sources:
A MEDLINE search (1966–May 2010) was conducted for English-language, human studies using the terms mitiglinide, KAD 1229, S 21403, and meglitinide analogs. Abstracts presented at the American Association and European Association for the Study of Diabetes annual meetings from 2005 to 2009 were also evaluated for relevant data.
Study Selection and Data Extraction:
Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide were reviewed.
Data Synthesis:
Mitiglinide has been shown through small clinical studies (N <400) to modestly decrease hemoglobin A1c, postprandial hyperglycemia, and oxidative stress and inflammatory markers associated with postprandial hyperglycemia. Mitiglinide exerts its hypoglycemic activity by closing adenosine triphosphate (ATP)–sensitive potassium channels in the β-islet cells of the pancreas. This agent has a rapid onset and short duration of action, mimicking a physiologic pattern of insulin release in nondiabetic people. Studies suggest a starting dose of 5 mg 3 times daily with meals and a maximum dose of 20 mg 3 times daily. Overall, mitiglinide is well tolerated, with the most common adverse effect being hypoglycemia.
Conclusions:
Mitiglinide is the third agent in the class of meglitinides that targets postprandial hyperglycemia. Because of a more intensive dosing regimen, potential cost, and lack of studies assessing the clinical impact of mitiglinide therapy on oxidative stress and inflammatory markers secondary to postprandial hyperglycemia, we cannot recommend this therapy over currently approved therapies.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1P136</identifier><identifier>PMID: 20841518</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Biological and medical sciences ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Humans ; Hypoglycemic Agents - pharmacokinetics ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Isoindoles - pharmacokinetics ; Isoindoles - pharmacology ; Isoindoles - therapeutic use ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>The Annals of pharmacotherapy, 2010-10, Vol.44 (10), p.1615-1623</ispartof><rights>2011 Harvey Whitney Books Company</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-5d71ea7ce8d216a19396aa2fdf31769f63799fdd058017968e6760ac63f73653</citedby><cites>FETCH-LOGICAL-c345t-5d71ea7ce8d216a19396aa2fdf31769f63799fdd058017968e6760ac63f73653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1345/aph.1P136$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1345/aph.1P136$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,778,782,21806,27911,27912,43608,43609</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23280298$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20841518$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Phillippe, Haley M</creatorcontrib><creatorcontrib>Wargo, Kurt A</creatorcontrib><title>Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>Objective:
To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus.
Data Sources:
A MEDLINE search (1966–May 2010) was conducted for English-language, human studies using the terms mitiglinide, KAD 1229, S 21403, and meglitinide analogs. Abstracts presented at the American Association and European Association for the Study of Diabetes annual meetings from 2005 to 2009 were also evaluated for relevant data.
Study Selection and Data Extraction:
Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide were reviewed.
Data Synthesis:
Mitiglinide has been shown through small clinical studies (N <400) to modestly decrease hemoglobin A1c, postprandial hyperglycemia, and oxidative stress and inflammatory markers associated with postprandial hyperglycemia. Mitiglinide exerts its hypoglycemic activity by closing adenosine triphosphate (ATP)–sensitive potassium channels in the β-islet cells of the pancreas. This agent has a rapid onset and short duration of action, mimicking a physiologic pattern of insulin release in nondiabetic people. Studies suggest a starting dose of 5 mg 3 times daily with meals and a maximum dose of 20 mg 3 times daily. Overall, mitiglinide is well tolerated, with the most common adverse effect being hypoglycemia.
Conclusions:
Mitiglinide is the third agent in the class of meglitinides that targets postprandial hyperglycemia. Because of a more intensive dosing regimen, potential cost, and lack of studies assessing the clinical impact of mitiglinide therapy on oxidative stress and inflammatory markers secondary to postprandial hyperglycemia, we cannot recommend this therapy over currently approved therapies.</description><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacokinetics</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Isoindoles - pharmacokinetics</subject><subject>Isoindoles - pharmacology</subject><subject>Isoindoles - therapeutic use</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0E1PwjAYwPHGaATRg1_A9KLGw7AvtF29EXxNQD1wX8r2FErGhu1mwre3COrFU5vml6dP_gidU9KnfCBuzXrRp--UywPUpWLAEskUOYx3IklCWEo66CSEJSFEU6aPUYeRdEAFTbvoeeIaNy9d5Qq4w0P8Wn9CiYdzqBpsa4-bBeCpB9Osti-1xdPNGjDD987MoIGAJ1CWrmnDKTqypgxwtj97aPr4MB09J-O3p5fRcJzkcdMmEYWiYFQOacGoNFRzLY1htrCcKqmt5EprWxREpIQqLVOQShKTS24Vl4L30PVu7NrXHy2EJlu5kMcdTAV1GzIlBFVccB3lzU7mvg7Bg83W3q2M32SUZNtsWcyWfWeL9mI_tZ2toPiVP50iuNwDE3JTWm-q3IU_x2NkprfuaueCmUO2rFtfxRj__PgFHAd_Ng</recordid><startdate>20101001</startdate><enddate>20101001</enddate><creator>Phillippe, Haley M</creator><creator>Wargo, Kurt A</creator><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20101001</creationdate><title>Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus</title><author>Phillippe, Haley M ; Wargo, Kurt A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-5d71ea7ce8d216a19396aa2fdf31769f63799fdd058017968e6760ac63f73653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacokinetics</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Isoindoles - pharmacokinetics</topic><topic>Isoindoles - pharmacology</topic><topic>Isoindoles - therapeutic use</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Phillippe, Haley M</creatorcontrib><creatorcontrib>Wargo, Kurt A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Phillippe, Haley M</au><au>Wargo, Kurt A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2010-10-01</date><risdate>2010</risdate><volume>44</volume><issue>10</issue><spage>1615</spage><epage>1623</epage><pages>1615-1623</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>Objective:
To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus.
Data Sources:
A MEDLINE search (1966–May 2010) was conducted for English-language, human studies using the terms mitiglinide, KAD 1229, S 21403, and meglitinide analogs. Abstracts presented at the American Association and European Association for the Study of Diabetes annual meetings from 2005 to 2009 were also evaluated for relevant data.
Study Selection and Data Extraction:
Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide were reviewed.
Data Synthesis:
Mitiglinide has been shown through small clinical studies (N <400) to modestly decrease hemoglobin A1c, postprandial hyperglycemia, and oxidative stress and inflammatory markers associated with postprandial hyperglycemia. Mitiglinide exerts its hypoglycemic activity by closing adenosine triphosphate (ATP)–sensitive potassium channels in the β-islet cells of the pancreas. This agent has a rapid onset and short duration of action, mimicking a physiologic pattern of insulin release in nondiabetic people. Studies suggest a starting dose of 5 mg 3 times daily with meals and a maximum dose of 20 mg 3 times daily. Overall, mitiglinide is well tolerated, with the most common adverse effect being hypoglycemia.
Conclusions:
Mitiglinide is the third agent in the class of meglitinides that targets postprandial hyperglycemia. Because of a more intensive dosing regimen, potential cost, and lack of studies assessing the clinical impact of mitiglinide therapy on oxidative stress and inflammatory markers secondary to postprandial hyperglycemia, we cannot recommend this therapy over currently approved therapies.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>20841518</pmid><doi>10.1345/aph.1P136</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1060-0280 |
| ispartof | The Annals of pharmacotherapy, 2010-10, Vol.44 (10), p.1615-1623 |
| issn | 1060-0280 1542-6270 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_755173539 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Biological and medical sciences Clinical Trials as Topic Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Humans Hypoglycemic Agents - pharmacokinetics Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Isoindoles - pharmacokinetics Isoindoles - pharmacology Isoindoles - therapeutic use Medical sciences Pharmacology. Drug treatments |
| title | Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T17%3A32%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mitiglinide:%20A%20Novel%20Agent%20for%20the%20Treatment%20of%20Type%202%20Diabetes%20Mellitus&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Phillippe,%20Haley%20M&rft.date=2010-10-01&rft.volume=44&rft.issue=10&rft.spage=1615&rft.epage=1623&rft.pages=1615-1623&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1P136&rft_dat=%3Cproquest_cross%3E755173539%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=755173539&rft_id=info:pmid/20841518&rft_sage_id=10.1345_aph.1P136&rfr_iscdi=true |